|1.||Clemens, John D: 11 articles (05/2014 - 09/2004)|
|2.||Acosta, Camilo J: 11 articles (05/2014 - 09/2004)|
|3.||Ochiai, R Leon: 10 articles (05/2014 - 09/2004)|
|4.||Ali, Mohammad: 8 articles (05/2014 - 09/2004)|
|5.||Danovaro-Holliday, M Carolina: 7 articles (04/2007 - 09/2004)|
|6.||Galindo, Claudia M: 7 articles (04/2007 - 09/2004)|
|7.||Ivanoff, Bernard: 6 articles (04/2007 - 09/2004)|
|8.||Pang, Tikki: 6 articles (04/2007 - 09/2004)|
|9.||Thiem, Vu Dinh: 5 articles (04/2007 - 09/2004)|
|10.||Levine, Myron M: 4 articles (08/2015 - 08/2004)|
|1.||Typhoid Fever (Typhoid)
08/03/2012 - "Vaccination strategies are important for prevention, and the Vi capsular polysaccharide (ViCPS) vaccine has been shown to be effective in reducing the burden of typhoid fever. "
12/01/2005 - "Efficacy of a locally produced, Chinese Vi polysaccharide typhoid fever vaccine during six years of follow-up."
09/29/2014 - "In this study it was shown that conjugation of PspA to Vi enhanced the anti-PspA response and that PspA was a suitable carrier protein as demonstrated by the characteristics of a T-cell dependent response to the Vi. We propose that a bivalent vaccine consisting of PspA from families 1 and 2 bound to Vi polysaccharide would protect against typhoid fever and has the potential to also protect against pneumococcal disease and should be considered for use in developing countries. "
01/01/2014 - "Vi polysaccharide vaccine (injection, one dose) A single dose of Vi polysaccharide vaccine prevents around two-thirds of typhoid cases in the first year after vaccination (Year 1: 69%, 95% CI 63% to 74%; three trials, 99,979 participants; high quality evidence). "
01/01/2007 - "Trial participation and vaccine desirability for Vi polysaccharide typhoid fever vaccine in Hue City, Viet Nam."
|2.||Hepatitis A (Hepatitis, Infectious)
01/01/2006 - "The proportion of adverse events in Vi polysaccharide and hepatitis A recipients will not be known until the end of the trial when the code is broken. "
09/01/2000 - "The single dose of vaccine contains 25 microg typhoid Vi polysaccharide and at least 1,440 ELISA units of inactivated hepatitis A in a 1 mL dose. "
05/01/2002 - "These results support the feasibility of extemporaneously syringe-mixed combined hepatitis A and B vaccine with a Vi polysaccharide typhoid vaccine, administered in healthy adults."
09/01/1998 - "The inactivated hepatitis A and Vi polysaccharide typhoid vaccines are safe and well tolerated when administered simultaneously (mixed or concomitant) and as a combined vaccine. "
05/01/2002 - "This clinical study evaluated the feasibility of extemporaneously syringe-mixed hepatitis A and B vaccine (Twinrix) and a Vi polysaccharide vaccine (Typherix) in healthy adults, and compared this to concomitant administration of the vaccines in separate arms. "
05/01/2002 - "The mixed dose of vaccine contained at least 720 enzyme-linked immunosorbent assay (ELISA) units of the inactivated hepatitis A antigen, 20 microg of the recombinant hepatitis B antigen and 25 microg of the Vi polysaccharide typhoid antigen in 1.5 mL. The study was conducted in 200 healthy 18- to 45-year-old volunteers. "
|2.||typhoid Vi polysaccharide vaccine (Typhim Vi)
|3.||Surface Antigens (Surface Antigen)
|4.||Immunoglobulin G (IgG)
|5.||O Antigens (O Antigen)
|8.||Tetanus Toxoid (Vaccine, Tetanus)
|10.||pneumococcal surface protein A